David Lehmann, MD
Ophthalmology · Columbus, OHNPI 1861478562
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $46,764 of the $57,785 with a category attached, or 80.9%. Aerie Pharmaceuticals, Inc. accounts for 73.1% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2019 at $19,104 and has fallen 99.9% since, to $29 in 2024. Among ophthalmology clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 89 payments — averaging $649.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Aerie Pharmaceuticals, Inc.$42K
- Alcon$11K
- AbbVie$4K
- Novartis$57
- Biotissue Holdings Inc.$36
- Boston Scientific$19
- plus $17 from 1 others
What the payments were for
- Consulting fees$1,9203%
- Speaking & faculty fees$46,76481%
- Travel & lodging$6,62211%
- Food & beverage$2,2114%
- Education$2670%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Aerie Pharmaceuticals, Inc. | 53 | $42,263 |
| Alcon | 7 | $11,396 |
| AbbVie(2 entities) | 22 | $3,997 |
| Novartis | 3 | $57 |
| Biotissue Holdings Inc. | 2 | $36 |
| Boston Scientific | 1 | $19 |
| Ivantis, Inc | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$57,785 in reported general payments places this provider in the 95th percentile of 640 ophthalmology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 400 | $185,925 |
| RocklatanNetarsudil Mesylat/Latanoprost | 139 | $76,685 |
| RhopressaNetarsudil Mesylate | 83 | $55,740 |
| VyzultaLatanoprostene Bunod | 124 | $50,187 |
| RestasisCyclosporine | 29 | $30,061 |
| Alphagan PBrimonidine Tartrate | 41 | $10,034 |
| CombiganBrimonidine Tartrate/Timolol | 31 | $8,895 |
| AzoptBrinzolamide | 17 | $7,717 |
| Brinzolamide | 41 | $7,022 |
| Cosopt PfDorzolamide/Timolol/Pf | 22 | $5,576 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 34 | $5,075 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 22 | $4,378 |
| Brimonidine Tartrate | 90 | $4,197 |
| Travoprost | 43 | $4,115 |
| Travatan ZTravoprost | 14 | $3,339 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Alphagan P, Combigan | $3,997 | $234,915501 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $42,263 | $132,425222 claims |
| AlconAzopt, Simbrinza | $11,396 | $12,09539 claims |
| NovartisTravatan Z | $57 | $3,33914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 640 ophthalmology providers in Ohio.
Other ophthalmology in Columbus
- Alice EpitropoulosColumbus$531K
- Steven KatzColumbus$256K
- Lisa BorkowskiColumbus$25K
- Thomas MendelColumbus$15K
- Norman BakerColumbus$11K
- Carrie LembachColumbus$11K
- John ChristoforidisColumbus$10K
- Peter KaiserCleveland$1.5M
- Gregory EippertMentor$813K
- Robert OsherCincinnati$720K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.